Top-Performer: "Induction of phenotypic changes in HER2-postive breast cancer cells in vivo and in vitro" Read the full study: https://t.co/GuJwnRkNHe #breastcancer #cancerresearch #medEd #OA https://t.co/dXHio3EHl3
Watch the #OncotargetShort video about a study on phenotypic changes in HER2+ breast cancer cells by researchers from @ClemsonUniv @NIH @theNCI & @FredNatLab. Read the full paper: https://t.co/GuJwnRkNHe #breastcancer #HER2 #OA #medED #cancer #cancer
Top-Performer: Read this high #Altmetric scoring paper published by Oncotaget in 2020, entitled: "Induction of phenotypic changes in HER2-postive breast cancer cells in vivo and in vitro" https://t.co/GuJwnRkNHe #breastcancer #medEd #OA #cancerresearch
RT @Dr_BBooth: Our latest paper out now in @Oncotarget. We make breast cancer cells act like normal cells. It's open access so there is not…
RT @Dr_BBooth: Our latest paper out now in @Oncotarget. We make breast cancer cells act like normal cells. It's open access so there is not…
RT @Dr_BBooth: Our latest paper out now in @Oncotarget. We make breast cancer cells act like normal cells. It's open access so there is not…
RT @Dr_BBooth: Our latest paper out now in @Oncotarget. We make breast cancer cells act like normal cells. It's open access so there is not…
Our latest paper out now in @Oncotarget. We make breast cancer cells act like normal cells. It's open access so there is not reason for you not to read it. https://t.co/8U0Xgx7nDi
The cover for issue 30 of @Oncotarget features Figure 4, "RNAseq results demonstrating differences between normal, cancer, and redirected cells," by Frank-Kamenetskii, et al. https://t.co/9Ek7uH080I